Clinical Trial Update: A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer. [Phase 1]

View source ↗

Summary

Phase I study of alemtuzumab in relapsed ovarian cancer and primary peritoneal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Alemtuzumab (Alemtuzumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Status: TERMINATED